Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Part of paid clinical trials in St. George, Utah.
- Sponsor
- Jason Ahee, M.D.
- Study ID
- NCT03244072
- Phase
- PHASE2/PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Endophthalmitis
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Moxifloxacin — DRUGIntracameral injection
- Placebo — DRUGintracameral injection
Study Details
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
Key Dates
- Start date
- Jun 1, 2026
- Status verified
- Aug 2025
- Primary completion
- Oct 31, 2030
- Completion
- Oct 31, 2031
Study Design
- Enrollment
- 60,000 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Active Comparator: Treatment groupIntracameral injection of moxifloxacin solution after cataract surgery
- Placebo Comparator: Placebo groupIntracameral injection of placebo after cataract surgery
Primary Outcome Measure
Endophthalmitis after cataract surgery [ Time Frame: Subjects will undergo eye examinations at one day, one week, and one month post-operatively ]
Central Contacts
- Jason Ahee, M.D.435-862-9865
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Zion Eye Institute | St. George | Utah | 84790 | Jason Ahee, M.D. |
Find similar trials in St. George, UT
By research site